Trial Profile
Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms SMS
- 26 Nov 2018 Status changed from active, no longer recruiting to completed.
- 05 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Dec 2008 New trial record.